<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="17549">delta-Aminolevulinic acid</z:chebi>-4-<z:chebi fb="0" ids="36927">[14C]</z:chebi> and [3H]-<z:chebi fb="0" ids="16990">bilirubin</z:chebi> were administered intravenously to five patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> and four healthy control subjects on two occasions: before and on days 10 through 14 of a course of <z:chebi fb="1" ids="8069">phenobarbital</z:chebi> (2.5 mg/kg/day) </plain></SENT>
<SENT sid="1" pm="."><plain>The resulting curves of [3H]-<z:chebi fb="0" ids="16990">bilirubin</z:chebi> and <z:chebi fb="0" ids="36927">[14C]</z:chebi>-<z:chebi fb="0" ids="16990">bilirubin</z:chebi> in plasma were analyzed by computer to determine a number of parameters of physiological interest </plain></SENT>
<SENT sid="2" pm="."><plain>As expected, <z:chebi fb="1" ids="8069">phenobarbital</z:chebi> produced a highly significant fall in the plasma concentration of unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> as a result of a significant increase in hepatic <z:chebi fb="0" ids="16990">bilirubin</z:chebi> clearance in <z:hpo ids='HP_0000001'>all</z:hpo> subjects; plasma <z:chebi fb="0" ids="16990">bilirubin</z:chebi> turnover was unaltered </plain></SENT>
<SENT sid="3" pm="."><plain>Surprisingly, the drug produced no change in the incorporation of <z:chebi fb="0" ids="36927">[14C]</z:chebi>-<z:chebi fb="0" ids="17549">delta-aminolevulinic acid</z:chebi> into <z:chebi fb="0" ids="36927">[14C]</z:chebi>-early labeled <z:chebi fb="0" ids="16990">bilirubin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>To explain this unexpected finding, the effects of <z:chebi fb="1" ids="8069">phenobarbital</z:chebi> (75 mg/kg/day for 6 days) on incorporation of <z:chebi fb="0" ids="36927">[14C]</z:chebi>-<z:chebi fb="0" ids="17549">delta-aminolevulinic acid</z:chebi> and 2-<z:chebi fb="0" ids="36927">[14C]</z:chebi>-glycine into <z:chebi fb="0" ids="36927">[14C]</z:chebi>-early labeled <z:chebi fb="0" ids="16990">bilirubin</z:chebi> and on the activity of the enzyme <z:chebi fb="0" ids="17549">delta-aminolevulinic acid</z:chebi> synthase were studied in nonfasted, adult, male Sprague-Dawley rats </plain></SENT>
<SENT sid="5" pm="."><plain>At the dose and duration of treatment used, <z:chebi fb="1" ids="8069">phenobarbital</z:chebi> administration increased total hepatic <z:chebi fb="0" ids="17549">delta-aminolevulinic acid</z:chebi> synthase activity and produced a significant increase of 70% in the incorporation of <z:chebi fb="0" ids="36927">[14C]</z:chebi>-glycine into early labeled <z:chebi fb="0" ids="16990">bilirubin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>By contrast, no increase in the incorporation of <z:chebi fb="0" ids="36927">[14C]</z:chebi>-<z:chebi fb="0" ids="17549">delta-aminolevulinic acid</z:chebi> into early labeled <z:chebi fb="0" ids="16990">bilirubin</z:chebi> was observed </plain></SENT>
<SENT sid="7" pm="."><plain>These data suggest that <z:chebi fb="0" ids="17549">delta-aminolevulinic acid</z:chebi> is an inappropriate precursor for studies of the rate of <z:chebi fb="4" ids="30413">heme</z:chebi> biosynthesis, presumably because it bypasses <z:chebi fb="0" ids="17549">delta-aminolevulinic acid</z:chebi> synthase, the physiological rate-limiting enzyme in the <z:chebi fb="4" ids="30413">heme</z:chebi> biosynthetic pathway </plain></SENT>
</text></document>